Consumer Staples · Perfumes, Cosmetics & Other Toilet Preparations

CL Colgate-Palmolive SEC Filings & Insider Trading Activity 2026

company
CIK 21665122 filings
S&P 500

CL at a glance

Colgate-Palmolive (CL, SEC CIK 21665) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Colgate-Palmolive (CL) reported revenue of $20.4 billion (up 1.4% from FY2024) and net income of $2.1 billion. Diluted EPS was $2.63.
  • As of September 30, 2026, 57 institutional investment managers tracked by SignalX reported holding Colgate-Palmolive (CL) shares worth $28.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Malcolm Gregory on November 10, 2026 of 4,100 shares at $97.97 per share.
  • In the last 90 days, CL insiders reported 0 open-market purchases ($0) and 6 open-market sales ($8.0M) on Form 4, a net sale of $8.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$20.4B
+1.4% vs prior year
Insiders · 90 days
0 buys · 6 sells
Net −$8.0M
13F holders
57 funds
$28.8B · −2 vs prior quarter
Latest 8-K
Oct 30, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Two-segment model: Oral/Personal/Home Care (77% combined net sales) and Pet Nutrition (23%), sold in 200+ countries
  • New C-suite hires: Shane Grant (COO Americas, ex-Danone) and John Hazlin (Chief Growth Officer) added in 2025
  • Explicit strategic emphasis on AI, social commerce, and omni-channel demand generation as growth drivers vs prior year
  • ~33,600 employees across 100+ countries; 84% outside the US, with Asia Pacific (33%) and Latin America (31%) as largest regions
  • Colgate owns "world's most penetrated brand": household penetration cited as a core KPI of 2030 business strategy

Management Discussion & Analysis

  • Revenue $20,382 in 2025, up 1.4% YoY; organic sales +1.4% driven by 2.1% net pricing, offset by -0.4% volume and -0.3% FX
  • GAAP operating margin 16.2% vs 21.2% (−500 bps) due to $919 pretax Filorga impairment; non-GAAP operating margin 21.3% vs 21.7% (−40 bps); gross margin 60.1% vs 60.5%
  • Best segment: Hill's Pet Nutrition, operating margin 23.1% vs 21.5% (+160 bps), revenue +2.9% to $4,613; worst: North America, revenue −1.6% to $4,045, operating margin 19.4% vs 20.4% (−100 bps)
  • Operating cash flow $4,198 (+2% YoY); capex $564; dividends $1,823 ($2.06/share); share buybacks $1,210 (13.7M shares); new $5B repurchase program authorized March 2025
  • Management expects 2025 category softness to persist into 2026; key risks include tariff-driven cost inflation, FX volatility, China weakness, and private-label trade-down; new Strategic Growth and Productivity Program targets $200–$300 pretax charges through 2028

Risk Factors

  • FDA and global regulators reviewing fluoride, titanium dioxide, synthetic colors, and PFAS in consumer products: reformulation or restriction could materially impact core product lines
  • Eurasia operations ~1% of consolidated net sales and ~2% of consolidated operating profit; cash repatriation from Russia blocked and financial institution access constrained
  • Single-source or limited-supplier dependencies for key raw/packaging materials; new supplier qualification requires significant time and capital investment
  • eCommerce and AI enabling direct-to-consumer competitors; key retailers leveraging AI-aided pricing algorithms and first-party data to pressure Colgate's shelf access and margins
  • Q4 2025 non-cash after-tax impairment charge of $794M on skin health business goodwill and intangible assets, signaling acquisition integration risk

AI summary of the CL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward regulatory risk: compliance with evolving global laws and regulations
  • Carried-forward operational risk: supply-chain disruptions affecting product availability
  • Carried-forward financial risk: foreign-currency fluctuations affecting reported results

AI summary of the CL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 net sales rose 4.6% to $5,369 million, with organic growth of 3.6%, signaling resilient underlying demand despite macro uncertainty
  • Base Business EPS increased 7% to $0.97, while gross margin expanded 90 basis points to 60.3%, supporting improved earnings quality

Item 2.02: Results of Operations and Financial Condition

  • Earnings release covers Colgate-Palmolive’s quarter ended September 30, 2026
  • Exhibit 99 contains the financial results and management commentary relevant to quarterly performance
Filed Jul 31, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Colgate-Palmolive reported earnings for the quarter ended June 30, 2026
  • Detailed financial results and management commentary are in Exhibit 99, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • Q2 net sales $5,361M, up 4.9%; organic growth 2.4%, indicating modest underlying demand after FX and portfolio effects
  • Base Business EPS $0.99, up 8%, while GAAP EPS fell 5% to $0.86 due partly to Strategic Growth and Productivity charges
Filed May 13, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Annual meeting held May 8, 2026; all 10 nominated directors elected, preserving board continuity
  • PwC ratified as independent auditor for year ending December 31, 2026, with 647,385,500 votes supporting

AI summaries of CL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CL

Don't miss the next CL filing

  • Alerts as it files. A push when CL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CL, by share count.
  • Ask anything. An AI agent that reads every CL filing and answers with sources.

CL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Malcolm GregorySellNov 10, 2026$97.97
NORRINGTON LORRIE MMNov 5, 2026$71.56
NORRINGTON LORRIE MMNov 5, 2026-
NORRINGTON LORRIE MSellNov 5, 2026$99.31
Wallace Noel R.SellNov 5, 2026$100.26
Hazlin JohnMNov 4, 2026$77.04
Hazlin JohnSellNov 4, 2026$99.15
Tsourapas PanagiotisMNov 4, 2026$76.41

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$19.5B$20.1B$20.4B
Gross Profit-$12.2B$12.3B
Operating Income$4.0B$4.3B$3.3B
Net Income-$2.9B$2.1B
Gross Margin-60.5%60.1%
Op. Margin20.5%21.2%16.2%
Net Margin-14.4%10.5%
Balance Sheet
Total Assets-$16.0B$16.3B
Equity$609.0M$212.0M$54.0M
ROE-1362.7%3948.1%
Per Share
EPS$2.77$3.51$2.63
Cash Flow
Operating CF-$4.1B$4.2B

Source: XBRL data in Colgate-Palmolive (CL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202657$28.82B
Q2 202659$31.07B
Q1 202657$29.44B
Q4 202558$26.20B
Q3 202559$26.95B
Q2 202558$30.57B
Q1 202555$21.67B
Q4 202451$17.93B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 454 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 12, 2026--
4Nov 9, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
8-KOct 30, 2026Analysis-
10-QOct 30, 2026Analysis
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 15, 2026--
4Sep 15, 2026--
4Sep 15, 2026--
4Sep 15, 2026--
4Sep 15, 2026--
4Sep 15, 2026--

Related Consumer Staples companies

All Consumer Staples →

CL SEC filings: frequently asked questions

Are CL insiders buying or selling?

In the last 90 days, Colgate-Palmolive (CL) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $8.0 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CL stock?

As of September 30, 2026, the largest Colgate-Palmolive (CL) holders among the 13F filers tracked by SignalX were BlackRock ($6.0 billion), Vanguard Capital Management LLC ($4.4 billion), State Street Corp ($4.0 billion), Vanguard Portfolio Management LLC ($3.0 billion), T. Rowe Price Group ($2.3 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Colgate-Palmolive (CL) reported revenue of $20.4 billion (up 1.4% from FY2024) and net income of $2.1 billion. Diluted EPS was $2.63. The figures come from the XBRL data in the 10-K.

What are the main risks in CL's latest 10-K?

In the 10-K filed February 23, 2026, Colgate-Palmolive (CL) flagged: FDA and global regulators reviewing fluoride, titanium dioxide, synthetic colors, and PFAS in consumer products: reformulation or restriction could materially impact core product lines. Eurasia operations ~1% of consolidated net sales and ~2% of consolidated operating profit; cash repatriation from Russia blocked and financial institution access constrained. (AI summary of the Risk Factors section.)

What did CL report in its latest 8-K?

Colgate-Palmolive (CL) filed an 8-K on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 net sales rose 4.6% to $5,369 million, with organic growth of 3.6%, signaling resilient underlying demand despite macro uncertainty.

What are the latest CL SEC filings?

Colgate-Palmolive (CL) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 20, 2026.

What is CL's SEC CIK number?

Colgate-Palmolive (CL)'s SEC Central Index Key (CIK) is 21665. EDGAR lists every CL filing under that number.

Ask anything about CL

The research agent reads CL's filings, financials, insider trades and 13F holders, then answers with sources.